Document is current
Any future updates will be listed below
-
Authors
Seidel, Maria
Geisler, Daniel https://orcid.org/0000-0003-2076-5329
Borchardt, Viola https://orcid.org/0000-0003-4928-051X
King, Joseph A. https://orcid.org/0000-0002-2864-5578
Bernardoni, Fabio https://orcid.org/0000-0002-5112-405X
Jaite, Charlotte
Roessner, Veit
Calhoun, Vince
Walter, Martin
Ehrlich, Stefan https://orcid.org/0000-0003-2132-4445
- License Information
-
More Information
Article History
Received: 11 March 2020
Revised: 14 September 2020
Accepted: 21 October 2020
First Online: 11 November 2020
Change Date: 24 December 2020
Change Type: Update
Change Details: A funding note needed to be added to fulfill the contractual requirement of the DEAL Fully OA agreement. The funding notes states: Open Access funding enabled and organized by Projekt DEAL.
Conflict of interest
: V.R. has received payment for consulting and writing activities from Lilly, Novartis, and Shire Pharmaceuticals; lecture honoraria from Lilly, Novartis, Shire Pharmaceuticals, and Medice Pharma; and support for research from Shire and Novartis. He has carried out (and is currently carrying out) clinical trials in cooperation with Novartis, Shire, and Otsuka. V.R. has no financial relationship with the organizations that sponsored the research. All other authors report no conflicts of interest.
